Synopsis
Synopsis
0
CEP/COS
0
VMF
0
Australia
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 1-(2-(2,4-dimethylphenylsulfanyl)phenyl)piperazine
2. Brintellix
3. Lu Aa21004
4. Lu-aa21004
5. Luaa21004
6. Vortioxetine
1. 960203-27-4
2. Vortioxetine Hbr
3. Brintellix
4. Vortioxetine (lu Aa21004) Hbr
5. Trintellix
6. Vortioxetine (hydrobromide)
7. Unii-tks641koay
8. Lu Aa 21004 Hydrobromide
9. Vortioxetine Hydrobromide [usan]
10. Lu Aa21004 Hbr
11. Tks641koay
12. Lu-aa21004 Hydrobromide
13. Lu Aa21004 (hbr)
14. 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine Hydrobromide
15. 960203-27-4 (hbr)
16. Chebi:76015
17. 1-(2-((2,4-dimethylphenyl)sulfanyl)phenyl)piperazine Monohydrobromide
18. Brintellix (tn)
19. 1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine Hydrobromide
20. 1-[2-[(2,4-dimethylphenyl)thio]phenyl]piperazine Hydrobromide
21. Piperazine, 1-(2-((2,4-dimethylphenyl)thio)phenyl)-, Hydrobromide (1:1)
22. Trintellix (tn)
23. Voltiocetin Hydrobromide
24. Lu Aa21004 Hydrobromide
25. Vortioxetine Monohydrobromide
26. Schembl237653
27. Lu-aa21004 Hbr
28. Chembl2107387
29. Lu-aa-21004
30. Dtxsid501027850
31. Amy25254
32. Bcp09588
33. Ex-a2348
34. Hy-15414a
35. Mfcd22383961
36. S8021
37. Vortioxetine Hydrobromide (jan/usan)
38. Akos016340374
39. Ccg-268394
40. Cs-1472
41. Hg-0011
42. Sb16507
43. Vortioxetine Hydrobromide [jan]
44. Ac-28325
45. Vortioxetine (lu Aa21004) Hydrobromide
46. Vortioxetine Hydrobromide [who-dd]
47. 960203-27-4, Trintellix, Brintellix,
48. Ft-0696676
49. Sw219360-1
50. D10185
51. Vortioxetine Hydrobromide [orange Book]
52. A855301
53. Lu Aa 21004 Hydrobromide;lu Aa21004 Hydrobromide
54. Q27145682
55. 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine-hbr
56. 1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine;hydrobromide
57. 1-[2-[(2,4-dimethylphenyl)thio]phenyl]-piperazine Hydrobromide
58. 1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine Hydrobromide
59. 4-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine Hydrobromide
60. 4-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazin-1-ium Bromide
1. Vortioxetine
| Molecular Weight | 379.4 g/mol |
|---|---|
| Molecular Formula | C18H23BrN2S |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 3 |
| Exact Mass | 378.07653 g/mol |
| Monoisotopic Mass | 378.07653 g/mol |
| Topological Polar Surface Area | 40.6 Ų |
| Heavy Atom Count | 22 |
| Formal Charge | 0 |
| Complexity | 316 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Brintellix |
| PubMed Health | Meclizine, Buclizine, and Cyclizine (Oral route, Parenteral route) |
| Drug Label | BRINTELLIX is an immediate-release tablet for oral administration that contains the beta () polymorph of vortioxetine hydrobromide (HBr), an antidepreant. Vortioxetine HBr is known chemically as 1-[2-(2,4-Dimethyl-phenylsulfanyl)-phenyl]-piperazi... |
| Active Ingredient | Vortioxetine hydrobromide |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | eq 15mg base; eq 5mg base; eq 20mg base; eq 10mg base |
| Market Status | Prescription |
| Company | Takeda Pharms Usa |
| 2 of 2 | |
|---|---|
| Drug Name | Brintellix |
| PubMed Health | Meclizine, Buclizine, and Cyclizine (Oral route, Parenteral route) |
| Drug Label | BRINTELLIX is an immediate-release tablet for oral administration that contains the beta () polymorph of vortioxetine hydrobromide (HBr), an antidepreant. Vortioxetine HBr is known chemically as 1-[2-(2,4-Dimethyl-phenylsulfanyl)-phenyl]-piperazi... |
| Active Ingredient | Vortioxetine hydrobromide |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | eq 15mg base; eq 5mg base; eq 20mg base; eq 10mg base |
| Market Status | Prescription |
| Company | Takeda Pharms Usa |
Treatment of major depressive episodes in adults.
Anti-Anxiety Agents
Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)
Antidepressive Agents
Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)
Selective Serotonin Reuptake Inhibitors
Compounds that specifically inhibit the reuptake of serotonin in the brain. (See all compounds classified as Selective Serotonin Reuptake Inhibitors.)
Serotonin 5-HT1 Receptor Agonists
Endogenous compounds and drugs that specifically stimulate SEROTONIN 5-HT1 RECEPTORS. Included under this heading are agonists for one or more of the specific 5-HT1 receptor subtypes. (See all compounds classified as Serotonin 5-HT1 Receptor Agonists.)
Serotonin 5-HT3 Receptor Antagonists
Drugs that bind to but do not activate SEROTONIN 5-HT3 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT3 RECEPTOR AGONISTS. (See all compounds classified as Serotonin 5-HT3 Receptor Antagonists.)
N06AX26
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41091
Submission : 2024-12-31
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2017-02-01
Pay. Date : 2016-12-27
DMF Number : 31281
Submission : 2016-12-30
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29849
Submission : 2016-08-15
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2017-04-13
Pay. Date : 2017-02-23
DMF Number : 31389
Submission : 2017-03-04
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2017-04-14
Pay. Date : 2017-03-03
DMF Number : 31314
Submission : 2017-03-01
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2017-05-17
Pay. Date : 2017-03-16
DMF Number : 31507
Submission : 2017-03-23
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2017-07-31
Pay. Date : 2017-05-11
DMF Number : 31411
Submission : 2017-02-28
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2017-02-03
Pay. Date : 2016-09-29
DMF Number : 30309
Submission : 2016-03-10
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2017-05-24
Pay. Date : 2017-03-27
DMF Number : 31583
Submission : 2017-03-31
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2017-06-28
Pay. Date : 2017-06-06
DMF Number : 31492
Submission : 2017-05-25
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Registration Number : 304MF10041
Registrant's Address : 7-2-A2,Hetero Corporate,Industrial Estates Sanath Nagar,Hyderabad-500 018 Telangana I...
Initial Date of Registration : 2022-02-24
Latest Date of Registration : 2022-02-24

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Date of Issue : 2023-06-28
Valid Till : 2026-09-12
Written Confirmation Number : SD230059
Address of the Firm : No. 127, Qizhong Avenue, Qihe County, Dezhou City, Shandong Province, China
Vardenafil Hydrochloride Trihydrate EP
Date of Issue : 2025-08-22
Valid Till : 2028-08-21
Written Confirmation Number : WC-0082
Address of the Firm : Karakhadi, Plot No. 842-843, At - Karakhdi, Tal. - Padra, Dist -Vadodara, Gujara...

Date of Issue : 2025-08-22
Valid Till : 2028-08-21
Written Confirmation Number : WC-0082
Address of the Firm : Karakhadi, Plot No. 842-843, At - Karakhdi, Tal. - Padra, Dist -Vadodara, Gujara...

Date of Issue : 2025-08-29
Valid Till : 2028-08-28
Written Confirmation Number : WC-0142
Address of the Firm : A-33, A-37/2/2 & A-2, M.I.D.C., Patalganga -410220, Taluka: Khalapur, District: ...

Date of Issue : 2025-09-03
Valid Till : 2028-08-08
Written Confirmation Number : WC-0041
Address of the Firm : Unit-I, Sy. No. 10, I.D.A, Gaddapotharam (V), Jinnaram (M), Sangareddy District,...

Date of Issue : 2025-10-01
Valid Till : 2028-07-02
Written Confirmation Number : WC-0087
Address of the Firm : Plot No.1 to 5, 31 to 35 & 48 to 51, 26 & Kl201, Village Lakhmapur, Taluka Dindo...

Date of Issue : 2025-09-08
Valid Till : 2028-08-15
Written Confirmation Number : WC-0022
Address of the Firm : Plot No. 182 to 186, 192-A and 193 to 197 & 212/A,B,C,D Phase-ll, IDA, Pashamyla...

Date of Issue : 2025-12-10
Valid Till : 2028-07-02
Written Confirmation Number : WC-0123
Address of the Firm : Sy. Nos. 7-70, 70/1 & 70/2, Digwal Village, Kohir Mandal, Sangareddy District, T...

Vortioxetine Hydrobromide (Beta form)
Date of Issue : 2025-08-19
Valid Till : 2028-08-08
Written Confirmation Number : WC-0382
Address of the Firm : Survey No. 353, Domadugu (V),Gummadidala (M), Sangareddy District,Pincode-502001...

Date of Issue : 2022-06-30
Valid Till : 2025-07-28
Written Confirmation Number : WC-0063
Address of the Firm : Plot No. 99, MIDC Area - Dhatav Roha, Dist. Raigad, Roha, Raigad-402116, Maharas...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Registrant Name : Seongwoo Chemical Co., Ltd.
Registration Date : 2022-09-16
Registration Number : Su473-29-ND
Manufacturer Name : Alembic Pharmaceuticals Limi...
Manufacturer Address : API Division Karakhadi, Plot No. 842-843 Tal-Padra, AT.- Karakhadi-391 450, Dist.- Va...

Registrant Name : Aging Life Science Co., Ltd.
Registration Date : 2023-06-13
Registration Number : Su434-57-ND
Manufacturer Name : Hetero Labs Limited (Unit-1)
Manufacturer Address : Sy.No.10, IDA,Gaddapotharam Village, Jinnaram Mandal, Sangareddy District, Pincode 50...

Registrant Name : Pharmapia Co., Ltd.
Registration Date : 2026-02-20
Registration Number : Su258-54-ND
Manufacturer Name : Shijiazhuang Lonzeal Pharmac...
Manufacturer Address : Industrial Zone, Shenze (No. 16 West Ring Road), Shijiazhuang, Hebei Province, 052560...

Registrant Name : Kukjeon Pharmaceutical Co., Ltd.
Registration Date : 2022-05-17
Registration Number : Su173-40-ND
Manufacturer Name : MSN Pharmachem Private Limit...
Manufacturer Address : Plot. No. 182 to 186, 192-A, 193 to 197 & 212/A,B,C,D, Phase-II, IDA Pashamylaram, Pa...

Registrant Name : Sangjin Trading Co., Ltd.
Registration Date : 2022-12-06
Registration Number : Su583-32-ND
Manufacturer Name : SYMED LABS LIMITED
Manufacturer Address : Unit-I, Survey No. 353, Domadugu (Village), Gummadidala (Mandal), Sangareddy (Dist.),...

Registrant Name : Wonpung Pharmaceutical Co., Ltd.
Registration Date : 2024-06-28
Registration Number : Su583-32-ND(2)
Manufacturer Name : SYMED LABS LIMITED
Manufacturer Address : Unit-I, Survey No. 353, Domadugu (Village), Gummadidala (Mandal), Sangareddy (Dist.),...

Registrant Name : Narsha Farm Co., Ltd.
Registration Date : 2023-04-13
Registration Number : Su583-32-ND(1)
Manufacturer Name : SYMED LABS LIMITED
Manufacturer Address : Unit-I, Survey No. 353, Domadugu(V),Gummadidala(M), Sangareddy (Dist.), 502001.Telang...

Registrant Name : Sampoong Pharmachem Co., Ltd.
Registration Date : 2025-04-07
Registration Number : Su582-27-ND
Manufacturer Name : Zhejiang Hisoar Chuannan Pha...
Manufacturer Address : No 23. 5th Donghai Avenue, Zhejiang Chemical materials base Linhai Zone, Linhai City,...

Registrant Name : Engchem Life Sciences Co., Ltd.
Registration Date : 2020-07-07
Registration Number : 238-7-ND
Manufacturer Name : Engchem Life Sciences Co., L...
Manufacturer Address : 59 Biovalley-ro, Jecheon-si, Chungcheongbuk-do

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for pharmaceutical and biotech industries. LGM also operates as a full-service CDMO, offering formulat...
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...
About the Company : HRV Pharma is a global manufacturer, seller, and exporter of APIs, intermediates, pellets, food-grade chemicals, food additives, and food ingredients. The company provides sourcing...
About the Company : Neuland Laboratories, established in 1984 and headquartered in Hyderabad, is a publicly listed company offering solutions for pharmaceutical chemistry needs—from library compound...
About the Company : Established in May 2012, Shandong Loncom Pharmaceutical is a wholly owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Located in the Qihe Economic Development Zone, Sh...
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
About the Company : Tenatra International was established as a proprietorship firm in 1999. It got off to a very good start, supporting clients in the United States, Mexico and Europe. As business opp...
About the Company : Cipla is a global pharmaceutical company whose goal is ensuring no patient shall be denied access to high quality & affordable medicine and support. Mission: Cipla’s mission i...

About the Company : Exemed, with due global accreditations from US FDA, KFDA and other regulatory bodies, is one of the leading and cost-competitive manufacturers of Metformin. Besides Metformin we ma...

About the Company : MANA PHARMA, S.L. is a Spanish Pharmaceutical Company, with Authorization as a Wholesale Pharmaceutical Distribution Entity of Medicines for Human Use as well as a Certificate of G...

About the Company : Nakoda Chemicals Ltd incorporated in 1989 is engaged in manufacturing, developing and marketing of Bulk API'S (Bulk Active Pharma Ingredients), Intermediates, Specialty chemicals a...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Vortioxetine is a small molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Depressive Disorder.
Lead Product(s): Vortioxetine Hydrobromide,Cariprazine Hydrochloride,Bupropion Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 05, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vortioxetine Hydrobromide,Cariprazine Hydrochloride,Bupropion Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vortioxetine is a small molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Depressive Disorder.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 05, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Vortioxetine HBr is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Depressive Disorder, Major.
Lead Product(s): Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 02, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder
Details : Vortioxetine HBr is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 02, 2025

Details:
Vortioxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Frontotemporal Dementia.
Lead Product(s): Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: National Institute on Aging | H. Lundbeck AS
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 19, 2024

Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : National Institute on Aging | H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia
Details : Vortioxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Frontotemporal Dementia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 19, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Lundbeck will cease all promotional efforts for Trintellix (vortioxetine hbr) with Takeda in the U.S. fully reallocate resources to other growth opportunities and accelerate growth for these products.
Lead Product(s): Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Trintellix
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 01, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Takeda Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Lundbeck Partners with Takeda in the US, Opts for Royalties, Focuses on Rexulti
Details : Lundbeck will cease all promotional efforts for Trintellix (vortioxetine hbr) with Takeda in the U.S. fully reallocate resources to other growth opportunities and accelerate growth for these products.
Product Name : Trintellix
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 01, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults. The product is approved in over 80 countries1 , including the US, EU, Canada and Australia.
Lead Product(s): Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Vortidif
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: H. Lundbeck AS
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 30, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : H. Lundbeck AS
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults. The product is approved in over 80 countries1 , including the US, EU, Canada and Australia.
Product Name : Vortidif
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 30, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
USFDA has given tentatively approved ANDA, a therapeutically equivalent reference listed drug product for Vortioxetine-Generic (Vortioxetine), indicated for the treatment of major depressive disorder.
Lead Product(s): Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Vortioxetine-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 07, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : USFDA has given tentatively approved ANDA, a therapeutically equivalent reference listed drug product for Vortioxetine-Generic (Vortioxetine), indicated for the treatment of major depressive disorder.
Product Name : Vortioxetine-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 07, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Vortioxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Depressive Disorder, Major.
Lead Product(s): Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Rawalpindi Medical College
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 03, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Rawalpindi Medical College
Deal Size : Inapplicable
Deal Type : Inapplicable
Vortioxetine as a Novel Anti-depressant With Improvement in Cognitive Abilities
Details : Vortioxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 03, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Vortioxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Depression.
Lead Product(s): Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 20, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Vortioxetine to Prevent Return of Symptoms in Children With Depression
Details : Vortioxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Depression.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 20, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
A new study shows that people living with Major Depressive Disorder (MDD) and comorbid Generalized Anxiety Disorder (GAD) benefit from treatment with vortioxetine as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS).
Lead Product(s): Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Trintellix
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 03, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A new study shows that people living with Major Depressive Disorder (MDD) and comorbid Generalized Anxiety Disorder (GAD) benefit from treatment with vortioxetine as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS).
Product Name : Trintellix
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 03, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
In a new real-world study, the ability of Trintellix/Brintellix® (vortioxetine) to improve functioning in family, social, and work life for people living with Major Depressive Disorder was assessed.
Lead Product(s): Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Trintellix
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 22, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vortioxetine Hydrobromide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In a new real-world study, the ability of Trintellix/Brintellix® (vortioxetine) to improve functioning in family, social, and work life for people living with Major Depressive Disorder was assessed.
Product Name : Trintellix
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 22, 2021

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CAS Number : 95-16-9
End Use API : Vortioxetine Hydrobromide
About The Company : Established in May 2012, Shandong Loncom Pharmaceutical is a wholly owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Located in the Qihe Economic ...
Bis(2-chloroethyl)amine hydrochloride
CAS Number : 821-48-7
End Use API : Vortioxetine Hydrobromide
About The Company : Established in May 2012, Shandong Loncom Pharmaceutical is a wholly owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Located in the Qihe Economic ...
2-[(2,4-Dimethylphenyl)thio]aniline hydrochloride
CAS Number : 1019453-85-0
End Use API : Vortioxetine Hydrobromide
About The Company : Established in May 2012, Shandong Loncom Pharmaceutical is a wholly owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Located in the Qihe Economic ...
CAS Number : 95-16-9
End Use API : Vortioxetine Hydrobromide
About The Company : Established in May 2012, Shandong Loncom Pharmaceutical is a wholly owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Located in the Qihe Economic ...
CAS Number : 4214-28-2
End Use API : Vortioxetine Hydrobromide
About The Company : Established in May 2012, Shandong Loncom Pharmaceutical is a wholly owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Located in the Qihe Economic ...
1-[2-(2,4-Dimethylphenylthio)phenyl]piperazine hyd...
CAS Number : 960203-28-5
End Use API : Vortioxetine Hydrobromide
About The Company : Established in May 2012, Shandong Loncom Pharmaceutical is a wholly owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Located in the Qihe Economic ...
CAS Number : 508233-74-7
End Use API : Vortioxetine Hydrobromide
About The Company : Established in May 2012, Shandong Loncom Pharmaceutical is a wholly owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Located in the Qihe Economic ...
CAS Number : 13616-82-5
End Use API : Vortioxetine Hydrobromide
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

CAS Number : 57260-71-6
End Use API : Vortioxetine Hydrobromide
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

CAS Number : 1493-27-2
End Use API : Vortioxetine Hydrobromide
About The Company : Anupam Rasayan India Limited was started in 1976 and we are 36 years old. ISO 9001:2008 and ISO 14001:2004 certified chemical company with sound technology, en...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2027-12-15
US Patent Number : 9861630*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 204447
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-12-15

Patent Expiration Date : 2027-06-15
US Patent Number : 9861630
Drug Substance Claim :
Drug Product Claim :
Application Number : 204447
Patent Use Code : U-1668
Delist Requested :
Patent Use Description : METHOD OF TREATING DEP...
Patent Expiration Date : 2027-06-15

Patent Expiration Date : 2027-12-15
US Patent Number : 9125909*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 204447
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-12-15

Patent Expiration Date : 2027-06-15
US Patent Number : 9125908
Drug Substance Claim :
Drug Product Claim :
Application Number : 204447
Patent Use Code : U-2309
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-06-15

Patent Expiration Date : 2027-12-15
US Patent Number : 11458134*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 204447
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-12-15

Patent Expiration Date : 2032-09-21
US Patent Number : 9278096*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 204447
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2032-09-21

Patent Expiration Date : 2027-12-15
US Patent Number : 9227946*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 204447
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-12-15

Patent Expiration Date : 2027-06-15
US Patent Number : 8969355
Drug Substance Claim :
Drug Product Claim :
Application Number : 204447
Patent Use Code : U-1668
Delist Requested :
Patent Use Description : METHOD OF TREATING DEP...
Patent Expiration Date : 2027-06-15

Patent Expiration Date : 2026-12-17
US Patent Number : 7144884*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 204447
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-12-17

Patent Expiration Date : 2027-06-15
US Patent Number : 9125909
Drug Substance Claim :
Drug Product Claim :
Application Number : 204447
Patent Use Code : U-2309
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-06-15

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : M-232
Exclusivity Expiration Date : 2026-08-23
Application Number : 204447
Product Number : 1
Exclusivity Details :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : M-232
Exclusivity Expiration Date : 2026-08-23
Application Number : 204447
Product Number : 2
Exclusivity Details :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : M-232
Exclusivity Expiration Date : 2026-08-23
Application Number : 204447
Product Number : 3
Exclusivity Details :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : M-232
Exclusivity Expiration Date : 2026-08-23
Application Number : 204447
Product Number : 4
Exclusivity Details :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : PED
Exclusivity Expiration Date : 2027-02-23
Application Number : 204447
Product Number : 1
Exclusivity Details :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : PED
Exclusivity Expiration Date : 2027-02-23
Application Number : 204447
Product Number : 2
Exclusivity Details :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : PED
Exclusivity Expiration Date : 2027-02-23
Application Number : 204447
Product Number : 4
Exclusivity Details :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : PED
Exclusivity Expiration Date : 2027-02-23
Application Number : 204447
Product Number : 3
Exclusivity Details :

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Patent Expiration Date : 2028-11-12
Date Granted : 2013-02-12
Brand Name : TRINTELLIX
Patent Number : 2705163
Filing Date : 2008-11-12
Strength per Unit : 5 mg
Dosage Form : TABLET
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2028-11-12
Date Granted : 2013-02-12

Patent Expiration Date : 2022-10-02
Date Granted : 2014-05-13
Brand Name : TRINTELLIX
Patent Number : 2462110
Filing Date : 2002-10-02
Strength per Unit : 5 mg
Dosage Form : TABLET
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2022-10-02
Date Granted : 2014-05-13

Patent Expiration Date : 2027-06-15
Date Granted : 2012-07-31
Brand Name : TRINTELLIX
Patent Number : 2655212
Filing Date : 2007-06-15
Strength per Unit : 5 mg
Dosage Form : TABLET
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2027-06-15
Date Granted : 2012-07-31

Patent Expiration Date : 2022-10-02
Date Granted : 2014-05-13
Brand Name : TRINTELLIX
Patent Number : 2462110
Filing Date : 2002-10-02
Strength per Unit : 10 mg
Dosage Form : TABLET
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2022-10-02
Date Granted : 2014-05-13

Patent Expiration Date : 2027-06-15
Date Granted : 2012-07-31
Brand Name : TRINTELLIX
Patent Number : 2655212
Filing Date : 2007-06-15
Strength per Unit : 10 mg
Dosage Form : TABLET
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2027-06-15
Date Granted : 2012-07-31

Patent Expiration Date : 2028-11-12
Date Granted : 2013-02-12
Brand Name : TRINTELLIX
Patent Number : 2705163
Filing Date : 2008-11-12
Strength per Unit : 10 mg
Dosage Form : TABLET
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2028-11-12
Date Granted : 2013-02-12

Patent Expiration Date : 2022-10-02
Date Granted : 2014-05-13
Brand Name : TRINTELLIX
Patent Number : 2462110
Filing Date : 2002-10-02
Strength per Unit : 15 mg
Dosage Form : TABLET
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2022-10-02
Date Granted : 2014-05-13

Patent Expiration Date : 2027-06-15
Date Granted : 2012-07-31
Brand Name : TRINTELLIX
Patent Number : 2655212
Filing Date : 2007-06-15
Strength per Unit : 15 mg
Dosage Form : TABLET
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2027-06-15
Date Granted : 2012-07-31

Patent Expiration Date : 2028-11-12
Date Granted : 2013-02-12
Brand Name : TRINTELLIX
Patent Number : 2705163
Filing Date : 2008-11-12
Strength per Unit : 15 mg
Dosage Form : TABLET
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2028-11-12
Date Granted : 2013-02-12

Patent Expiration Date : 2022-10-02
Date Granted : 2014-05-13
Brand Name : TRINTELLIX
Patent Number : 2462110
Filing Date : 2002-10-02
Strength per Unit : 20 mg
Dosage Form : TABLET
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2022-10-02
Date Granted : 2014-05-13

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
19
PharmaCompass offers a list of Vortioxetine Hydrobromide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Vortioxetine Hydrobromide manufacturer or Vortioxetine Hydrobromide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Vortioxetine Hydrobromide manufacturer or Vortioxetine Hydrobromide supplier.
PharmaCompass also assists you with knowing the Vortioxetine Hydrobromide API Price utilized in the formulation of products. Vortioxetine Hydrobromide API Price is not always fixed or binding as the Vortioxetine Hydrobromide Price is obtained through a variety of data sources. The Vortioxetine Hydrobromide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A TRINTELLIX manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of TRINTELLIX, including repackagers and relabelers. The FDA regulates TRINTELLIX manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. TRINTELLIX API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of TRINTELLIX manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A TRINTELLIX supplier is an individual or a company that provides TRINTELLIX active pharmaceutical ingredient (API) or TRINTELLIX finished formulations upon request. The TRINTELLIX suppliers may include TRINTELLIX API manufacturers, exporters, distributors and traders.
click here to find a list of TRINTELLIX suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A TRINTELLIX DMF (Drug Master File) is a document detailing the whole manufacturing process of TRINTELLIX active pharmaceutical ingredient (API) in detail. Different forms of TRINTELLIX DMFs exist exist since differing nations have different regulations, such as TRINTELLIX USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A TRINTELLIX DMF submitted to regulatory agencies in the US is known as a USDMF. TRINTELLIX USDMF includes data on TRINTELLIX's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The TRINTELLIX USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of TRINTELLIX suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The TRINTELLIX Drug Master File in Japan (TRINTELLIX JDMF) empowers TRINTELLIX API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the TRINTELLIX JDMF during the approval evaluation for pharmaceutical products. At the time of TRINTELLIX JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of TRINTELLIX suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a TRINTELLIX Drug Master File in Korea (TRINTELLIX KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of TRINTELLIX. The MFDS reviews the TRINTELLIX KDMF as part of the drug registration process and uses the information provided in the TRINTELLIX KDMF to evaluate the safety and efficacy of the drug.
After submitting a TRINTELLIX KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their TRINTELLIX API can apply through the Korea Drug Master File (KDMF).
click here to find a list of TRINTELLIX suppliers with KDMF on PharmaCompass.
A TRINTELLIX written confirmation (TRINTELLIX WC) is an official document issued by a regulatory agency to a TRINTELLIX manufacturer, verifying that the manufacturing facility of a TRINTELLIX active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting TRINTELLIX APIs or TRINTELLIX finished pharmaceutical products to another nation, regulatory agencies frequently require a TRINTELLIX WC (written confirmation) as part of the regulatory process.
click here to find a list of TRINTELLIX suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing TRINTELLIX as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for TRINTELLIX API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture TRINTELLIX as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain TRINTELLIX and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a TRINTELLIX NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of TRINTELLIX suppliers with NDC on PharmaCompass.
TRINTELLIX Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of TRINTELLIX GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right TRINTELLIX GMP manufacturer or TRINTELLIX GMP API supplier for your needs.
A TRINTELLIX CoA (Certificate of Analysis) is a formal document that attests to TRINTELLIX's compliance with TRINTELLIX specifications and serves as a tool for batch-level quality control.
TRINTELLIX CoA mostly includes findings from lab analyses of a specific batch. For each TRINTELLIX CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
TRINTELLIX may be tested according to a variety of international standards, such as European Pharmacopoeia (TRINTELLIX EP), TRINTELLIX JP (Japanese Pharmacopeia) and the US Pharmacopoeia (TRINTELLIX USP).